PT-141 (Bremelanotide) is the only FDA-approved peptide for female sexual dysfunction. Unlike peripheral treatments, it works centrally in the brain to increase sexual desire and arousal at the neurological level — addressing the root cause of HSDD rather than just its symptoms.
PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system — the brain regions governing sexual desire and motivation. This central mechanism is fundamentally different from peripheral treatments: it increases the neurological drive for sexual activity rather than just improving physical response.
MC4R activation triggers dopamine release in the mesolimbic reward pathway, the same system activated by natural sexual desire. This increases motivation, anticipation, and the subjective experience of sexual arousal — addressing the 'wanting' component of sexual response that is often impaired in HSDD.
As a secondary effect of central arousal signaling, PT-141 increases genital blood flow and lubrication. This peripheral effect is mediated by the autonomic nervous system response to central arousal, not by direct vascular action — explaining why PT-141 works for arousal disorders that do not respond to PDE5 inhibitors.
Start at 0.5 mg to assess nausea tolerance. Most women find 1 mg effective with a better side effect profile than the full 1.75 mg FDA dose.
| Phase | Dose | Timing | Notes |
|---|---|---|---|
| First use (test dose) | 0.5 mg SubQ | 45–60 min before activity | Assess nausea and BP tolerance. Take with a light meal to reduce nausea. |
| Standard dose | 1 mg SubQ | 45–60 min before activity | Most women find 1 mg effective with fewer side effects than 1.75 mg. |
| FDA-approved dose | 1.75 mg SubQ | 45–60 min before activity | Maximum recommended dose. Increase only if 1 mg is insufficient. |
| Frequency limit | Max 1 dose/24h | Max 8 doses/month | Clinical use limit. Hyperpigmentation risk increases with higher frequency. |
| Feature | PT-141 | Flibanserin (Addyi) | Topical Estrogen | Lubricants |
|---|---|---|---|---|
| Mechanism | Central (MC4R, dopamine) | Central (serotonin/dopamine) | Peripheral (estrogen) | Peripheral (moisture) |
| Onset | 45–60 min | 4–8 weeks | 2–4 weeks | Immediate |
| Use pattern | On-demand | Daily | Daily | As needed |
| FDA approved (HSDD) | Yes (Vyleesi) | Yes (Addyi) | No | No |
| Alcohol restriction | None | Yes (serious) | None | None |
| Main side effect | Nausea (40%) | Dizziness, somnolence | Local irritation | None |
≥99% purity, third-party COA verified. Use code HEALTH for 15% off.
Shop PT-141 at Purgo LabsPT-141 (Bremelanotide) is an MC4R agonist researched for female sexual dysfunction — specifically Hypoactive Sexual Desire Disorder (HSDD), female sexual arousal disorder, and orgasmic dysfunction. Unlike PDE5 inhibitors (Viagra, Cialis) which work peripherally on blood flow, PT-141 acts centrally in the brain to increase sexual desire and arousal at the neurological level. It is the only peptide with FDA approval for female sexual dysfunction (as Vyleesi).
The FDA-approved dose for women is 1.75 mg subcutaneously, administered 45 minutes before sexual activity. Research protocols use 0.5–2 mg per dose. Women should start at 0.5–1 mg to assess tolerance before increasing to 1.75 mg. PT-141 is used on-demand (not daily) — maximum frequency is once every 24 hours, and no more than 8 doses per month in clinical use.
PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system, increasing dopamine release in the mesolimbic pathway. This central mechanism directly increases sexual desire, arousal, and motivation — addressing the neurological component of female sexual dysfunction that peripheral treatments (lubricants, topical estrogen) cannot reach. Effects begin within 45–60 minutes and last 6–12 hours.
Yes — PT-141 (Bremelanotide/Vyleesi) has FDA approval specifically for HSDD in premenopausal women. Phase 3 RECONNECT trials showed statistically significant improvements in satisfying sexual events (SSEs) and sexual desire scores vs placebo. Women in the trials reported an average increase of 0.5 SSEs per month and significant reductions in distress related to low desire. Effects are modest but clinically meaningful.
Yes — PT-141 addresses both desire (wanting sex) and arousal (physical and psychological response during sex). The MC4R activation in the hypothalamus increases genital blood flow and lubrication as a secondary effect of central arousal signaling. Women with arousal disorders who do not respond to topical treatments may benefit from PT-141's central mechanism.
The most common side effects in women are nausea (40% in trials), flushing (20%), and injection site reactions (15%). Nausea typically peaks 1–2 hours post-injection and resolves within 4 hours. Taking PT-141 with a light meal reduces nausea. Transient blood pressure increases (systolic +6 mmHg) occur in some women — those with cardiovascular conditions should consult a healthcare provider. Hyperpigmentation (skin darkening) can occur with repeated use.
No significant pharmacokinetic interactions between PT-141 and oral contraceptives or HRT have been documented. PT-141 does not affect estrogen, progesterone, or androgen levels. Women on HRT for menopause-related sexual dysfunction may find PT-141 complementary — HRT addresses the hormonal substrate (estrogen, testosterone) while PT-141 addresses the central neurological component of desire.
Both PT-141 (Vyleesi) and flibanserin (Addyi) are FDA-approved for HSDD in premenopausal women. PT-141 is on-demand (taken before activity), while flibanserin is taken daily. PT-141 has a faster onset (45 min vs 4–8 weeks for flibanserin) and no alcohol interaction restriction. Flibanserin has a more established long-term safety profile. PT-141 is generally preferred for situational use; flibanserin for chronic daily management.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.